Page 29 - Solid Tumors News Today

/PRNewswire/ -- The "Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors,...

The trial evaluated whether adding radiation (SBRT) to immunotherapy (ICIs) could improve outcomes in a cohort with a variety of advanced solid tumors.

The FDA has granted orphan drug designation to padeliporfin vascular targeted photodynamic therapy for use as a potential therapeutic option in patients with locally advanced pancreatic cancer.

1. Baseline mGPS measures reliably predict the prognostic outcome of treatment in patients with metastatic renal cell carcinoma (mRCC) 2. On-treatment mGPS can provide prognostic information before the first radiologic staging and may permit therapy adjustments earlier in the treatment course. Evidence Rating Level: 1 (Excellent) Study Rundown: The modified Glasgow prognostic score (mGPS) is

Researchers at Fox Chase Cancer Center have utilized banked computed tomography to evaluate alternate response criteria for early prediction of outcomes in rare pancreatic neuroendocrine tumors.

23.06.2023 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy (sacituzumab govitecan) as monotherapy for the ...

Kura Oncology (NASDAQ:KURA – Get Rating) had its price objective boosted by Stifel Nicolaus from $24.00 to $25.00 in a research note published on Monday, The Fly reports. KURA has been the subject of several other reports. HC Wainwright restated a buy rating and issued a $32.00 price target on shares of Kura Oncology in […]

Kura Oncology (NASDAQ:KURA – Get Rating) had its target price increased by Stifel Nicolaus from $24.00 to $25.00 in a research note published on Monday morning, The Fly reports. Several other research firms have also issued reports on KURA. JMP Securities reissued a market outperform rating and issued a $22.00 target price on shares of […]

Kura Oncology, Inc. (NASDAQ:KURA – Get Rating)’s stock price traded down 3.6% on Thursday . The company traded as low as $11.04 and last traded at $11.06. 912,644 shares changed hands during mid-day trading, an increase of 32% from the average session volume of 692,360 shares. The stock had previously closed at $11.47. Analyst Ratings […]

Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price […]